XBiotech suspends rheumatological program due to phase II study results irregularities

From GlobeNewswire: 2024-12-23 19:53:07

XBiotech suspends clinical program for rheumatological conditions due to phase II study results. Study did not meet primary endpoint due to substantial irregularities. Planned studies for arthritis and ankylosing spondylitis on hold for evaluation. Study included 230 subjects with moderate to severe rheumatoid arthritis, assessing Natrunix with methotrexate. Irregularities involved sites recruiting most subjects, some multiple times. Results under analysis for implications. XBiotech specializes in True Human™ antibody-based therapeutics, with Natrunix cloned from donors with natural immunity. Headquartered in Austin, XBiotech has manufacturing facilities, research labs, and clinical centers. Contact Wenyi Wei for more info.



Read more at GlobeNewswire: XBiotech suspend son programme de rhumatologie